tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael Ulz, 133 are a BUY (66.5%), 61 are a HOLD (30.5%), 6 are a SELL (3%).
Analyst Michael Ulz, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 55.27% that have a potential upside of 40.84% achieved within 194 days.
Michael Ulz’s has documented 413 price targets and ratings displayed on 49 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on DYN, Dyne Therapeutics at 03-Mar-2026.
Analyst best performing recommendations are on KPTI (KARYOPHARM THERAPEUTICS).
The best stock recommendation documented was for KPTI (KARYOPHARM THERAPEUTICS) at 10/9/2025. The price target of $21 was fulfilled within 1 day with a profit of $152.85 (87.92%) receiving and performance score of 879.21.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 05-May-2021
$205
$22.5 (12.33%)
4 years 10 months 11 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold Since 23-Mar-2021
$173
$-9.5 (-5.21%)
$156
4 years 10 months 13 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold Since 14-Dec-2020
$190
4 years 10 months 18 days ago
(26-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Buy Since 06-Sep-2019
$175
$-7.5 (-4.11%)
$165
5 years 1 months 12 days ago
(04-Feb-2021)
3/3 (100%)
$19.41 (12.48%)
397
Hold Since 04-Feb-2021
$166
$-16.5 (-9.04%)
$175
5 years 1 months 12 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Which stock is Michael Ulz is most bullish on?
Which stock is Michael Ulz is most reserved on?
What Year was the first public recommendation made by Michael Ulz?
